HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lendvai, B. Articles by Vizi, E. S. Search for Related Content PubMed PubMed Citation Articles by Lendvai, B. Articles by Vizi, E. S.

Nonsynaptic Chemical Transmission Through Nicotinic Acetylcholine Receptors

Department of Pharmacology, Institute of Experimental Medicine, Hungarian Academy of Sciences, and Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary

ABSTRACT

I. INTRODUCTION

II. A NEW AVENUE IN NICOTINIC FUNCTION: UNIQUE ROLE OF NONSYNAPTIC NICOTINIC ACETYLCHOLINE RECEPTORS IN CHEMICAL TRANSMISSION

A. Morphological Evidence of Cholinergic Boutons Without Synaptic Contacts and Release of ACh Into the Extracellular Space

B. Nonsynaptic Localization of nAChRs

C. Mismatch Between AChE and ChAT Immunoreactivity

D. Operation of Nicotinic Transmission in the Nonsynaptic Mode

III. PRESYNAPTIC AND/OR PRETERMINAL NICOTINIC ACETYLCHOLINE RECEPTORS: RELEASE BY RECEPTOR STIMULATION

A. Location of nAChRs

B. Subtypes of nAChRs Involved in the Release of Transmitters

IV. NONSYNAPTIC MODULATION OF SYNAPTIC TRANSMISSION BY NICOTINIC ACETYLCHOLINE RECEPTORS

A. Receptors Mediating Synaptic Transmission

B. Modulation of Synaptic Transmission by Nicotine

V. NICOTINIC FUNCTIONS BEYOND SYNAPTIC TRANSMISSION

A. Hippocampal Interneurons

B. Interneurons of the Cortex and Striatum

C. Pyramidal Neurons

VI. NONSYNAPTIC NICOTINIC ACETYLCHOLINE RECEPTORS AND HIGHER BRAIN FUNCTIONS

A. Role of Nonsynaptic nAChR in Smoking

B. Therapeutic Potential of nAChR Stimulation on Cognition and Nonsynaptic Transmission

GRANTS

ACKNOWLEDGMENTS

REFERENCES

	ABSTRACT

Top Next References

	I. INTRODUCTION

Top Previous Next References

 
It is generally accepted that chemical transmission at the synapse is the primary method of conveying a message from one neuron to another. In addition to synaptic transmission, neurochemical (175–177) and morphological (25) evidence has revealed the significance of nonsynaptic interactions between neurons: transmitters are released from axon terminals without conventional synaptic contacts that do not appose a postsynaptic density. In this case, the transmitter is released into the extracellular space (12–18% of brain volume) (116), diffuses, and influences the activity of other neurons through stimulation of extrasynaptically located receptors. These receptors are mainly high-affinity metabotropic receptors that are sensitive to monoamines (norepinephrine, dopamine, serotonin) (177). However, it has been shown that synaptically released glutamate not only acts locally at intrasynaptic receptors, but it also escapes from the synaptic cleft to exert remote effects on nonsynaptic and channel-operated NR2B N-methyl-D-aspartate (NMDA) receptors (19, 144). In addition, a tonic current was described in cerebellar granule cells (154) that reflects the action of high-affinity GABA_A receptors (119) by ambient concentrations of GABA present in extrasynaptic space.

Recently, strong evidence was obtained demonstrating that a high proportion of cholinergic boutons (86–93%) in the central nervous system (CNS) do not make synaptic contacts (26, 74) but are still able to release acetylcholine (ACh) into the extracellular space (80). ACh, released in this way, reaches only low concentrations (0.1–2 µM) and may only have an effect on high-affinity receptors. Surprisingly, the ion-channel operated nAChRs of the CNS are mainly found in nonsynaptic localization (70). nAChRs, involved in the presynaptic modulation of transmitter release, are not postsynaptic receptors (180, 189).

Today, it is well established that nAChRs are highly permeable to Na⁺, K⁺, and Ca²⁺. The relatively large Ca²⁺ flux through the receptor (145, 173) provides extra power for nAChRs to efficiently modulate subcellular signaling cascades. Experiments on 4* knock-in mice, which have been sensitized to nicotine, revealed that nicotine can interact with nAChRs even at very low concentrations. Although the resolution of current optical methods may be insufficient to reveal small changes in intracellular Ca²⁺ under normal conditions (159), the nAChR-induced Ca²⁺accumulation helps these "fast" receptors create significant responses at the level of intracellular Ca²⁺. In addition to nAChRs, brain metabotropic muscarinic acetylcholine receptors (mAChRs) are also important receptors of ACh signaling. The operation of the muscarinic subsystem fits well with the nonsynaptic nature of ACh, producing tonic and much slower responses following cholinergic activity, compared with nicotinic responses. ACh released into the extracellular space is able to diffuse far away from release sites. The role of acetylcholinesterase (AChE) is to keep extrasynaptic, ambient level of ACh within physiological limits. Nonsynaptic transmission operates at a slower time-scale compared with synaptic transmission and is responsible for tonic changes in brain activity (176, 177). However, the ion-channel-type nAChRs produce considerably faster responses than metabotropic receptors, which is an observation that is inconsistent with the nonsynaptic theory. nAChR-mediated effects seem to be slow because their activation occurs after a rather long-lasting diffusion of the endogenous ligand to the receptor, but at the same time, they are fairly fast because of rapid ion flux through their ion channels following activation.

What experimental approach can be applied for studying nonsynaptic transmission via nAChRs? If one defines synaptic transmission as an event that occurs at the postsynaptic membrane, then presynaptic receptors are predominantly nonsynaptic because of the lack of axo-axonic synapses in most cell-to-cell contacts in many regions of the brain. Therefore, the majority of actions mediated by presynaptic nAChRs are nonsynaptic (182). Another possible way of investigation on nonsynaptic transmission is to study the effect of agonist ejection in small volume. Nonsynaptic and high-affinity excitatory nAChRs are activated under this condition because the fast dilution eliminates the agonist before it could enter the synapse at appropriate concentrations. Today, the challenge is to interpret how nAChRs use their ion channels to generate responses at the relatively slow time-scale of nonsynaptic transmission. This review attempts to address this issue and to partly resolve the contradictions. Details of the subtype composition (16, 49, 87) that shape central nicotinic functions, molecular biology (16), as well as structure and channel properties (114, 158) of nAChRs have been comprehensively reviewed recently (18, 107) and are beyond the focus of this paper.

	II. A NEW AVENUE IN NICOTINIC FUNCTION: UNIQUE ROLE OF NONSYNAPTIC NICOTINIC ACETYLCHOLINE RECEPTORS IN CHEMICAL TRANSMISSION

Top Previous Next References

 
A. Morphological Evidence of Cholinergic Boutons Without Synaptic Contacts and Release of ACh Into the Extracellular Space

Ultrastructural morphometric studies have revealed that the cholinergic axons of the adult rat parietal cortex (169) and hippocampus (168) rarely make synapses on other neurons. In layer 5 of the parietal cortex of young rats, the majority (66%) of the cholinergic boutons can be found in synaptic contact, but most of these synapses are symmetric, indicating muscarinic transmission (166). In older rats, cholinergic boutons establish significantly fewer synapses than in young animals (166). In the developing brain (postnatal day 16–32), the synaptic incidence of varicosities is 6% in the cortex (11) and 17% in the hippocampus, respectively (112). These numbers are quite close to the adult values of 7 and 14% (169, 168). These observations support the idea that ACh participates primarily in nonsynaptic interactions reaching its receptor via nonsynaptic routes (27). The position of cholinergic axons can be identified by staining for vesicular ACh transporter immunoreactivity, which is strongest in the stratum oriens of the CA1 region within the hippocampus (164), indicating that the cholinergic input may predominantly target the basal dendrites of pyramidal neurons and local interneurons. Although less evident, ACh synthesis [shown by choline acetyltransferase (ChAT)-immunostained varicosities] is also more pronounced in the strata pyramidale and oriens than in the radiatum or lacunosum moleculare (11). Another important piece of evidence for the nonsynaptic nature of the cholinergic system is the localization of AChE. The fact that AChE can be found at areas distinct from cholinergic axon terminals and nAChRs (57, 122, 178) suggests that the enzyme must sense and degrade ACh molecules that have already traveled far in the extracellular space. This assumption is consistent with the nonsynaptic nature of most cholinergic boutons. We can assume that ACh released from terminals without synaptic contact diffuses in the extracellular space to reach remote receptors, and this action is terminated by extracellular AChE. Thus it is not surprising that neostigmine, an AChE inhibitor, enhances the extracellular level of norepinephrine (NE) measured by microdialysis (80). Before its degradation by G4 form of AChE (26), the released ACh stimulates nAChRs of noradrenergic terminals causing NE release. Therefore, the slower degradation of ACh leads to an expansion of the volume transmission of NE.

Brain microdialysis, which samples from the extracellular space, further supports the nonsynaptic mechanism of action for nAChRs by showing changes in extracellular ACh levels during different treatments. It seems that the effect of ACh released from cholinergic boutons is tonic in several brain areas: neostriatal cholinergic interneurons produce spontaneous tonic firing in the absence of synaptic input and evoke a tonic release of ACh (12). Similarly, the released ACh keeps the striatal dopaminergic terminal under tonic control (195). The tonic mode of cholinergic transmission also favors the involvement of nAChRs in nonsynaptic transmission. A continuous, low level of transmitters is characteristic of extracellular information exchange, as the removal of the message from a large volume can never be as efficient as it is at the synapse. In contrast, there is evidence for the participation of cholinergic boutons in synaptic transmission in the cerebral cortex where two-thirds of the cholinergic axon terminals form synaptic specializations. However, the large majority of these cholinergic synapses are symmetric, indicating the inhibitory nature of transmission, most likely mediated by mAChRs (152). Indeed, electrophysiological measurements of synaptic currents revealed mAChR-mediated cholinergic transmission in associational-commissural synapses of the hippocampal CA3 region (184).

B. Nonsynaptic Localization of nAChRs

There have been a number of observations of nAChRs at nonsynaptic sites (Fig. 1) (31, 58–59, 62–64, 167, 186). In chicken ciliary ganglion neurons, nAChRs contribute to both synaptic (nicotinic) and nonsynaptic transmission: 3/5 nAChR mediate synaptic responses, while 7 nAChRs appear at perisynaptic locations (59, 186). The existence of 7 nAChRs in the chick ciliary ganglion has been shown earlier by -bungarotoxin labeling (66). Ultrastructural studies using labeled -bungarotoxin have revealed that most 7 nAChRs are located predominantly in nonsynaptic (at peri- and extrasynaptic loci) regions of axon terminals, with only 12% of labeled terminals showing synaptic 7 nAChRs (70). Low- versus high-affinity human 4β2 nAChRs can be separated by the different conductance levels of nicotinic currents (15). The high-affinity 4β2 nAChRs correspond most likely to nonsynaptic nAChRs receptors, which normally sense very low concentrations of the endogenous agonist ACh.

View larger version (74K): [in this window] [in a new window]   FIG. 1. Possible locations of nonsynaptic nicotinic acetylcholine receptors (nAChRs). A: presynaptic axon terminals without synaptic contacts and containing various transmitters can also be equipped with nAChRs whose stimulation results in transmitter release. B: dendritic nAChRs are located extrasynaptically at most neurons receiving cholinergic messages via nAChRs. C: nAChRs may occur inside the synapse. In glutamatergic synapses, their location is postsynaptic but the activation requires nonsynaptic routes, i.e., release of ACh from a nonsynaptic varicosity. In this case, the diffusion of ACh into the synapse is even more difficult.

Nonsynaptic nAChRs do not restrict to extrasynaptic membranes of neurons. nAChRs are also expressed in nonneuronal cells in the nervous system (149). For example, microglial cells and hippocampal astrocytes contain nAChRs (43, 151, 160). Because of the lack of synapses, ACh can only reach these cells by diffusion. Functionally, the 4, 7, β2, and β3 subunits and related Ca²⁺ channel responses have been found in primary rat astrocytes (191). The presence of nAChRs on these cells also implies a broader scope for the actions of nicotine that needs to be considered from a clinical viewpoint (149). Clinically, an increase in the proportion of astrocytes expressing 7 immunoreactivity was observed in Alzheimer's disease (160). This may contribute to alterations in Ca²⁺ homeostasis and could interfere with β-amyloid-mediated inflammatory processes (191). The activation of microglia, brain mononuclear phagocyte cells, establishes an endogenous "cholinergic anti-inflammatory pathway" via 7 nAChR in the peripheral nervous system. The most likely function of these nAChRs is to inhibit lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF)- release (151). These data indicate that nAChRs on nonexcitable cells may also represent an additional mechanism underlying the neuroprotective properties of nicotine.

C. Mismatch Between AChE and ChAT Immunoreactivity

The above findings support the hypothesis that the main function of nAChRs is to mediate nonsynaptic transmission. However, the widespread distribution of AChEs, which degrade the released ACh, also raises further questions. It can be speculated that the large number of degrading enzymes could stop the action of extracellular ACh. However, AChE and the ChAT distributions do not overlap perfectly. The mismatch between AChE and ChAT immunoreactivity (57) has been clearly shown in the retina (22) and in the rat interpeduncular nucleus (76). In the rodent cerebral cortex, ChAT-immunoreactive neurons do not contain detectable AChE activity, indicating that the released ACh is not degraded immediately after release. Thus ACh must diffuse a certain distance to reach its receptors while the surrounding AChEs create a "nonsynaptic tunnel" by degrading ACh at particular positions (92). Supporting the permissive role of AChE for ACh diffusion, central cholinergic pathways can be established in AChE knockout animals by butyrylcholinesterase substitution (113). It has already been proposed that the high extracellular level of AChE aims primarily to keep the concentration of ACh within limits, in time and in space, rather than to totally eliminate the released ACh (26). Furthermore, the degradation product of ACh, choline, can activate 7 nAChRs. In this regard, AChE-rich patches in brain tissue may relate to areas controlled by 7 nAChRs. The other uncertainty regarding the nonsynaptic nature of nicotinic transmission derives from the question of how a fast ion-channel-type receptor, like the nAChR, is capable of sensing the slowly building ACh levels around the receptor. Below, we made an attempt to provide an answer to this question.

D. Operation of Nicotinic Transmission in the Nonsynaptic Mode

With the assumption that cholinergic varicosities are in close proximity to remote elements, the released ACh should diffuse a relatively short distance to reach its receptors (as compared, for example, with the monoamine system; see Fig. 2). In this regard, the nature of this form of nonsynaptic transmission is different from monoamine transmission (176–177). A large and fluctuating monoamine pool in the extracellular matrix of the brain continuously modulates cell excitability and synaptic transmission. In contrast, nicotinic communication must represent a faster form of nonsynaptic transmission operating at shorter distances. Nevertheless, this form of interneural communication might be still much slower than synaptic transmission. The shorter distance allows a short diffusion time of ACh so that the fast response on the target dendrite may appear within the physiological time limits of neural integration. Membrane nicotinic ion channels mediate fast Na⁺ and Ca²⁺ influx, indeed, but the subsequent Ca²⁺ accumulation below the receiver membrane takes longer. Slow Ca²⁺ accumulation is corroborated by membrane voltage-sensitive Ca²⁺ channels and by Ca²⁺ release from intracellular stores (13, 29, 78, 142, 148, 153, 157, 174, 181). The Ca²⁺ influx through the nAChR can add to the Ca²⁺ response induced by synaptic activity or action potential back-propagation, which may lead to supralinear addition of inputs. Overall, nicotinic transmission can be taken as "fast nonsynaptic transmission." How can different time-scale transmission types work together? Based on the structural data regarding cholinergic boutons and remote neurons, one can assume a neuronal assembly of relatively close elements. Very distant pairs of elements (boutons and dendrites) are unlikely because AChE activity would then turn off most of the cholinergic message. Of course, these neuronal elements do not (or very rarely) form a synapse, but the diffusion barrier may be much smaller than that of the monoaminergic system. In one cell of the network, the cholinergic message may come shortly after a glutamatergic excitation as a second wave of excitation. Changes in monoamine levels can only slowly modulate the response of the cell. An ACh pulse from a nearby cholinergic bouton can increase the concentration of ACh around the remote cell and activate local nAChRs, which have just recovered from desensitization. The assumption of close, but not synaptic, appositions of cholinergic boutons and their targets is in line with the mismatch localization of ChAT (at the release site) and AChE (at the target neuron). Following a short diffusion, ACh can activate remote receptors, and this effect is promptly terminated by the closely located AChE (Fig. 2). In this regard, the effect on the target neurons appears secondary to synaptic activity, but still faster than the effect of monoamine neuromodulators (Fig. 2). Therefore, the activated receptors are able to evoke a large Ca²⁺ influx through the receptor (especially in the case of the 7 nAChR), leading to a local excitation of the host cell. Overall, ACh molecules arriving nonsynaptically can activate extrasynaptic nAChRs, or synaptic hetero-nAChRs in glutamatergic or GABAergic synapses, resulting in fast nonsynaptic transmission.

View larger version (59K): [in this window] [in a new window]   FIG. 2. Schematic drawing of the contribution of fast nonsynaptic transmission mediated by nAChRs relative to fast synaptic and slow monoaminergic nonsynaptic transmission. In this example, we assume simultaneous activation of glutamate-, monoamine-, and ACh-containing boutons, which converge to one target dendrite (gray). Note that the distributions of acetylcholinesterase (AChE) and choline-acetyltransferase (ChAT) enzymes do not overlap. Diffusion of ACh is limited by the high density of AChE, providing relatively shorter delay in action on target neurons, while the monoamines, such as noradrenaline/norepinephrine (NA), serotonin (5-HT), and dopamine (DA) diffuse over larger distances because they do not make synaptic contacts. Left panel (synaptic): target receptors are first activated by the released glutamate because of the high speed of synaptic transmission. Middle panel (channel-operated nonsynaptic): ACh, released from a nearby bouton, can reach the target after traveling a short distance between the cholinergic boutons and the receptive dendrite. Right panel (metabotropic nonsynaptic): the released monoamines have to pass a much larger distance. Thus they arrive at the target dendrite later, when the glutamatergic and cholinergic activation are over.

	III. PRESYNAPTIC AND/OR PRETERMINAL NICOTINIC ACETYLCHOLINE RECEPTORS: RELEASE BY RECEPTOR STIMULATION

Top Previous Next References

nAChRs located in the axon have been described in various brain regions. Because of the low incidence of axo-axonic synapses in most areas of the brain, ACh must diffuse to these receptors from nearby release sites. Thus axonal (in a wider sense "presynaptic") nAChRs may represent one target of nonsynaptic transmission. Activation of these receptors may induce regenerative spikes, which ultimately lead to release of transmitters in a tetrodotoxin (TTX)-dependent manner. These receptors, residing on axon terminals and/or preterminal axon branches typically far from the release site, have been termed preterminal receptors (88, 89, 187–189). In some cases, the term presynaptic receptors is limited to receptors located very close to the release site (89). Because of the close proximity to the release site, these receptors can influence release directly while avoiding the use of voltage-sensitive Na⁺ channels. The closer the receptor to the release site, the less sensitive it is to TTX. Nevertheless, both preterminal and presynaptic receptors should be at nonsynaptic sites of the axon because of the scarcity of axo-axonic synapses. Why are presynaptic/preterminal nAChRs so important for understanding cholinergic transmission? First of all, activation of presynaptic nAChRs that precedes or coincides with the arrival of an action potential into the terminal region of the neuron can increase the probability of release via the integrative capabilities of nAChR-induced Ca²⁺ influx. Indeed, catecholamine release could be elicited by the application of nicotinic agonists through mobilization of intracellular Ca²⁺ in chromaffin cells (42). The enhancement of miniature excitatory postsynpatic currents (mEPSCs) by nicotinic agonists in hippocampal pyramidal neurons is sufficient to drive the postsynaptic cell above the threshold for firing action potentials through synchronization of the release process (148). Nicotinic action on transmitter release evoked by electrical field stimulation is a useful indicator of presynaptic receptors, as the field stimulation opens all channels in the field, including Na⁺ and Ca²⁺ channels of the axon terminal. Thus the evoked release can be modulated only by local presynaptic receptors. Upstream (somatic) activity, either excitatory or inhibitory, exerts less or no influence on the evoked release. In addition, nicotine can induce release independent of action potentials (67).

There has been accumulating neurochemical evidence for the transmitter releasing action of presynaptic/preterminal nAChRs (180, 181). Activation of nAChRs in the hippocampus leads to the release of NE (139, 146, 179), GABA (83, 101), and serotonin (90, 156). In the striatum, nicotinic stimulation evokes the release of ACh (140), glutamate (162), dopamine (DA) (20, 24, 30, 50, 105, 153, 165), and serotonin (132). Brief pulses of low (3 µM) concentrations of nicotine, which do not induce desensitization of nAChRs, can cause a large enhancement of DA release evoked by high K⁺ application in striatal synaptosomes by altering the size of the readily releasable pool of vesicles (165). Evidence has been provided for preterminal nAChRs on GABAergic axons in the rat interpeduncular nucleus (89). One mechanism by which GABA release could be enhanced is the insertion of 7 nAChRs into axon terminals (192). Nicotine, epibatidine, and anatoxin-a can evoke the release of D-[³H]aspartate in a Ca²⁺-dependent manner in frontal cortex slices (135). Nicotine enhances glutamate release via 7 nAChRs from synaptosomes isolated from rat prefrontal cortex (185). In accordance with the neurochemical evidence for nAChRs modulating glutamate release, 7 nAChRs are present in approximately one-third of the glutamatergic axon terminals in the ventral tegmental area (VTA) (70). Stimulation of nAChRs in this region also causes DA release in the nucleus accumbens through the indirect activation of midbrain NMDA receptors (143). In cultured hippocampal neurons, fluorescent 7 nAChRs highly colocalize with synaptotagmin, which labels active axon terminals (193), further confirming the presynaptic/preterminal function of the 7 subtype. The presynaptic 7 nAChR seems cell-type specific; for example, cholinergic boutons apparently lack nAChRs (70).

B. Subtypes of nAChRs Involved in the Release of Transmitters

Different subtypes of nAChRs can be involved in the presynaptic regulation of transmitter release. The 3β2 nAChR has been suggested to induce NE release from acute hippocampal slices (146, 179) and striatal DA release (86). The 3β2-like nAChR-induced release of NE was TTX dependent in hippocampal slices (146). In contrast, using hippocampal synaptosomes, 3β4-like nAChRs were found to mediate the release of NE because the subtype-selective -conotoxin AuIB blocked the nicotine-evoked release (98). In addition, the 3β2 selective -conotoxin MII was ineffective in preventing nicotine-evoked NE release from synaptosomes (98). The TTX sensitivity of the 3β2 responses in the slice preparation suggests a preterminal localization of this receptor subtype for the hippocampal NE release. Taken together, we can conclude that the most likely structure for the nicotinic modulation of the noradrenergic innervation of the hippocampus consists of 3β4 nAChRs on the terminals and 3β2 receptors in upper segments of the axon. This can be explained by assuming that stimulation of 3β2 receptors may produce local regenerative potentials, which further increase the release by the additional Na⁺ influx. β2-Containing nAChRs are involved in the regulation of GABA release in the thalamus (88). In the superior cervical ganglion, activation of nAChRs enhanced the electrical field stimulation-induced release of ACh, most likely via 7 nAChRs (96). This kind of modulation represents a positive feedback for the ACh release. The role of 7 subtype is supported by the finding that 7 nAChR-mediated currents can also be measured in cultured superior cervical ganglion neurons (97). In addition, two different splice variants of 7 nAChRs have been detected in the superior cervical ganglion with distinct desensitization properties (23, 147). In the case NE release, 3β4 nAChRs were assumed for both TTX-sensitive and TTX-insensitive release forms in cultured sympathetic neurons (85). Later, the participation of 5 subunits was also linked to the presynaptic facilitation of NE release (32). Looking at the binding of radioligands, 3β4 was shown to be the dominant subtype, but axonal receptors for modulating the release were not identified separately from those mediating synaptic transmission on the postsynaptic side (121). The observation, that not only the 7 transcript, but also 3, 5, β2, and β4 transcripts are present in the superior cervical ganglion of rats (102), supports the view that distinct subtypes of nAChRs may be responsible for different presynaptic/postsynaptic nicotinic functions in the superior cervical ganglion. Activation of nAChRs could induce an increase in the intracellular Ca²⁺ level via 7 nAChRs in presynaptic neurites of developing microexplants (110), in cultured chick sympathetic neurons (29), and in hippocampal mossy fibers (52). Overall, the nicotinic subtype selectivity of presynaptic/preterminal actions potentially provides a tool to separately enhance certain nonsynaptic functions, i.e., spillover of glutamate or region-specific monoamine release.

Nicotinic agonists may combine their actions on presynaptic/preterminal nAChRs with an effect on transmitter uptake molecules resulting in compound release mechanisms (79, 81, 82, 90, 141, 156). The relative proportions of receptorial and nonconventional effects of dimethylphenylpiperazinium (DMPP) are determined by the concentration of the agonist (156). High Na⁺ concentration around the transporter may change the direction of transport to release transmitter instead of taking it up. A nicotinic agonist, lobeline, can increase DA release in a Ca²⁺-independent way (161). These nonclassical nicotinic actions can be antagonized only poorly or not at all by mecamylamine (128, 156). When nicotine enters the brain during smoking, these nonclassical receptor and transporter actions further increase the complexity of the system-level effects observed in humans.

	IV. NONSYNAPTIC MODULATION OF SYNAPTIC TRANSMISSION BY NICOTINIC ACETYLCHOLINE RECEPTORS

Top Previous Next References

 
To estimate the impact of nonsynaptic nAChRs in neural circuit, we need to understand how nAChRs influence synaptic functions. In particular, the major aim of this discussion is to review how hard-wired connections between cell types combine with the slower time-scale modulatory effects of nonsynaptic nAChRs. To demonstrate the nonsynaptic effects of nAChRs, we first summarize the limited number of cases where nAChRs mediate synaptic transmission in the brain. Then, the highly effective and widespread nicotinic modulation of fast synaptic transmission will be reviewed.

A. Receptors Mediating Synaptic Transmission

There is only scattered experimental evidence for functional nAChRs, which mediate synaptic transmission. Some of these studies have been designed using the "remaining current principle," i.e., the nicotinic antagonist-sensitive current following the block of all other synaptic currents. With the use of this approach, nicotinic synapses have been detected in stratum radiatum and oriens interneurons (6, 33), in hippocampal CA1 pyramidal cells (54), in pyramidal cells and interneurons of the developing visual cortex (134), in cells of the supraoptic nucleus (53), and in chick ciliary ganglion neurons (150). However, it is somewhat surprising that only 20% of stratum radiatum interneurons exhibit fast synaptic transmission mediated by nAChRs in acute hippocampal slices (6). Despite the fact that most interneurons (90%) express currents in response to application of nicotinic agonists (33–34), 7-mediated synaptic responses can be detected in only 14% of the cells, strongly suggesting that nonsynaptic transmission, and not synaptic transmission, may be the principal method of nicotinic transmission in interneurons. McQuiston and Madison (111) did not find any fast synaptic response mediated by nAChRs in interneurons, most likely because of the different methods of tissue preparation. With the assumption of a sparse distribution of nicotinic synapses over the dendrites of interneurons, many cells in the slice preparation may lack intact nicotinic synapses because of the angle of the cut or the selective degradation of superficial cells and dendrites. Nevertheless, the impact of the nicotinic synapses on interneuron dendrites is much less than the weight of glutamatergic inputs, which can be activated in 100% of the cells. These data favor the hypothesis that most nicotinic inputs of interneurons are not synaptic.

This is even more characteristic for hippocampal pyramidal neurons where synaptic currents mediated by nAChRs can only be dissected from a synaptic current of at least 1 nA amplitude (54). Taking this observation in conjunction with an earlier morphological study showing cholinergic synapses on pyramidal neurons (41), it seems that the contribution of nicotinic synapses to the synaptic innervation of pyramidal neurons is small. Most of the cholinergic synaptic innervation may conduct muscarinic-type responses including Ca²⁺ waves (126).

In the supraoptic nucleus, nicotinic excitatory postsynaptic potentials (EPSPs) are also mediated via 7 nAChRs similar to hippocampal interneurons (53). Non-7 nAChRs (150) can also contribute to synaptic transmission. In chick ciliary ganglion neurons, which innervate the iris and the choroid body, perisynaptic 7 nAChRs cooperate with fast synaptic currents mediated by non-7 nAChRs (17, 194). nAChRs located on somatic spines of chick ciliary ganglion neurons mediate fast synaptic transmission confined to spines (150). During high-frequency synaptic stimulation (50 Hz), non-7 nAChRs appear to mediate the Ca²⁺ transients confined to spines, and the sustained Ca²⁺ signal shows a decrement as an indication of receptor desensitization (150). Synaptic transmission through 3 subunit-containing nAChRs has been identified in the sympathetic ganglia (109, 129). Both 7 and non-7 nAChRs contribute to the remaining synaptic currents following the elimination of GABA and glutamatergic transmission, suggesting a synaptic role for nAChRs in dopaminergic neurons of the substantia nigra (108).

B. Modulation of Synaptic Transmission by Nicotine

Bath application of nicotinic drugs in low concentration is a frequently used experimental approach to study nicotinic modulatory actions. This method of drug delivery simulates the action of low extracellular ACh concentrations, which occur during normal neural activity, and even more importantly, it corresponds well with the effects of low-dose nicotine during cigarette smoking. Low concentrations of the agonist are not expected to interfere with synaptic transmission because the receptors in the synapse accommodate high (millimolar) concentrations of the synaptic transmitter (177, 182). In this regard, the dominant mode of the nicotinic effect is to influence, rather than mediate, synaptic transmission through nAChRs. Especially in the case of presynaptic nicotinic actions, the nonsynaptic form of interneuronal communication predominates.

In fact, the activation of presynaptic 7 nAChRs by extracellular ACh or choline facilitates glutamatergic synaptic currents in cultured hippocampal neurons (127), in CA1 and CA3 pyramidal neurons of the hippocampus (69, 100, 148), in olfactory bulb-amygdala preparations (48), and in pyramidal neurons of the rat auditory cortex (10).

Non-7 nAChRs may also contribute to the facilitation of glutamatergic synaptic events in the medial habenula-interpeduncular nucleus (48). Non-7 nAChRs, presumably of the 3β4 subtype, control the glutamatergic input to CA1 stratum radiatum interneurons (2). Additional evidence for the role of non-7 nAChRs in the modulation of synaptic transmission comes from studies on thalamocortical synapses showing that bath application of 1 µM nicotine facilitates synaptic responses (46). Bath application of 1 µM nicotine increases the AMPA-mediated excitatory postsynaptic current amplitude via 7 nAChRs in VTA dopaminergic neurons through a presynaptic/preterminal mechanism (103). Activation of nAChRs can release aspartate from the frontal cortex using neurochemical methods, supporting the nicotinic enhancement of glutamatergic transmission (135). Corroborating the functional studies, 7 nAChRs have been identified in VTA glutamatergic axon terminals (70). There is experimental evidence for functional nAChRs on GABAergic axon terminals as well. Bath-applied nicotine enhances the frequency of giant depolarizing potentials (depolarizing GABA release) during the early postnatal development of CA3 pyramidal neurons (101), and bath-applied nicotine increases spontaneous inhibitory currents in CA1 pyramidal neurons in organotypic slices (61).

The mechanism of synaptic enhancement most likely involves the activation of presynaptic nAChRs that causes Ca²⁺ influx into the axon terminal and induces transmitter release. Low-dose nicotine can increase mEPSC frequency and presynaptic Ca²⁺ influx (47, 52, 100, 110). This effect is TTX insensitive. Therefore, fast depolarization by voltage-sensitive Na⁺ channels can be excluded in these cases. In addition to the presynaptic enhancement of synaptic potentials, which appears as an increased frequency of EPSCs, there could be postsynaptic amplification by nAChRs as well. For example, low-dose nicotine can enhance synaptic transmission by increasing the amplitude of evoked glutamatergic EPSCs via postsynaptic nAChRs in the interpeduncular nucleus and in the hippocampus (110, 148). It should be noted that large-amplitude mEPSCs may appear in the absence of postsynaptic effects by preferential release of large vesicles, selective activation of synapses with larger synaptic potentials, or through the synchronization of release from more active zones (148).

	V. NICOTINIC FUNCTIONS BEYOND SYNAPTIC TRANSMISSION

Top Previous Next References

 
There is a large amount of experimental data regarding nicotinic transmission that is hard to explain on the basis of synaptic transmission. As it was discussed above, ACh is released into the extracellular space and, therefore, cholinergic transmission is primarily associated with a nonsynaptic form of communication in the CNS. "Postsynaptic" nAChRs mostly receive messages forwarded to extrasynaptic membranes. Thus it is more precise to define them as somatodendritic receptors. Although only a few studies discuss nAChRs directly as extrasynaptic receptors, there are many indications of nonsynaptic operations during nicotinic stimulation.

In the early study of Rovira et al. (136) using in vivo field recordings, ACh and the classical nicotinic agonist DMPP, applied to the somata of pyramidal neurons, enhanced population spikes (many coordinated action potentials), while application of ACh directly onto the dendrite increased dendritic inhibition. The enhancement of population spikes evoked by a very high concentration (800 µM) of nicotine, applied in the bath, was still prevented by mecamylamine despite the high concentration of the agonist (38). Nicotine was proposed to have a preferential net inhibitory effect on hippocampal basket cells and an excitatory effect on oriens/alveus interneurons (130, 131). In the following sections, several examples are provided of how nAChRs can interact with various neural functions at the cellular level, most likely through a nonsynaptic mechanism of action. Because central nAChRs have been extensively studied in the hippocampus, we provide a short overview of nAChR function in this region.

A. Hippocampal Interneurons

While it is known that the GABAergic portion of the septohippocampal innervation produces disinhibition in the hippocampus (163), much less is understood about the function of the cholinergic part of the septohippocampal projection. The most likely targets of the cholinergic septohippocampal pathway are the GABAergic interneurons. Although a population of hippocampal interneurons inhibits other interneurons, raising the possibility of a nicotine-induced disinhibition (39), this indirect excitation by the GABAergic loop does not appear in pyramidal neurons of the hippocampus under normal circumstances (14). However, in the case of high GABAergic activity, disinhibition can be observed in pyramidal neurons as a reduction of spontaneous GABA_A-mediated currents (68). In the dentate gyrus, nicotinic stimulation of hilar and subgranular interneurons consistently produces inhibition in granule cells via 7 nAChRs (35). Hippocampal inhibitory interneurons are markedly excited by activation of nAChRs (7, 34, 72, 111). Large currents can be evoked by application of nicotinic agonist onto stratum radiatum interneurons that persist even when voltage-sensitive Na⁺ and Ca²⁺ channels or synaptic glutamate and GABA receptors are blocked (3, 34, 72), indicating a postsynaptic/dendritic localization of these nAChRs. This also highlights that nAChRs, which receive the message of the septohippocampal cholinergic neurons, are largely located outside of the synapse. Selective nicotinic ligands induce firing of action potentials in a concentration-dependent manner (3, 4). At concentrations above 30 µM, nicotine is able to evoke action potentials in all interneurons. In contrast, at 10–15 µM nicotine concentrations, only a fraction (50%) of the neurons can respond (4). It seems unlikely that nicotinic drugs at the applied concentration (10–30 µM) could activate low-affinity synaptic nAChRs and induce a synaptic current. It is much more likely that the involved nAChRs are of high affinity and located at extrasynaptic membranes, indicating the role of nonsynaptic transmission. Stimulation of nAChRs also induces fast Ca²⁺ responses in stratum radiatum interneurons (183). There is a subtype heterogeneity among hippocampal interneurons at different localizations. 7 nAChRs have been found to "sense" the nicotinic message on stratum radiatum interneurons while stimulation of 4β2 nAChRs in stratum lacunosum moleculare interneurons induces a current with very little desensitization (4, 9, 111). nAChRs, expressed in interneurons of the hippocampus, can be excited by nicotine at concentrations found in smokers (4). Again, this finding implies that these receptors are of high affinity and suggests a role of nonsynaptic nicotinic transmission for hippocampal interneurons. All interneurons in the stratum radiatum and stratum lacunosum moleculare can be excited by nicotinic ligands, but many interneurons in the pyramidal cell layer do not respond (111).

Interneurons play an important role in the neural circuit of the hippocampus. Stratum radiatum interneurons primarily mediate feed-forward inhibition because they receive inputs from fibers entering the CA1 that mostly inhibit dendrites of pyramidal neurons. Therefore, nicotinic stimulation can shift the balance of inhibition/excitation in a slower time-scale, likely integrating a few consecutive synaptic events, as would be expected from a nonsynaptic message with a relatively large Ca²⁺ accumulation on the second scale. Nicotinic currents through functional nAChRs of hippocampal interneurons have been confirmed in carbachol uncaging experiments, revealing a decremental scaling of the nicotinic responses along the dendrite (77). Nicotinic excitation in interneurons can interact with network activity: simultaneous activation of AMPA and NMDA receptors boosts the postsynaptic nicotinic current in interneurons of the hippocampus (5).

B. Interneurons of the Cortex and Striatum

Certain types of cortical layer 5 interneurons can be excited by puff application of nicotinic agonists, providing a substrate for fine control of information flow in cortical networks (190). Both 7- and 4β2-like nAChRs are located on the somatodendritic regions of human cortical interneurons and mediate agonist-induced currents, while in the preterminal regions of the axon and/or in presynaptic terminals the 4β2 type dominates the nAChR population and results in GABA release (8). In layer 2/3 of the neocortex, the majority of irregular and regular spiking interneurons respond to DMPP via activation of postsynaptic non-7 nAChRs (124). In contrast, fast spiking interneurons and pyramidal neurons of cortical layer 2/3 seem to lack postsynaptic nAChRs (124). Nicotinic agonists, pressure applied onto the cells, depolarize striatal interneurons and induce firing through non-7 nAChRs, which, together with presynaptic inhibition through muscarinic receptors, form a dual cholinergic control on spiny interneurons of the striatum (84). The stimulation of nAChRs causes depolarization of dorsal raphe neurons indirectly via ₁-adrenoceptors (95). This effect is possibly mediated through facilitated release of NE. In addition, activation of nAChRs can also induce hyperpolarization on raphe neurons through 5-HT_1A receptors (95). In this case, a nAChR-mediated 5-HT release must be involved. In some cases, dendritic nAChR-mediated actions can be even more sensitive to external nicotine exposure than presynaptic nAChRs. The affinity of nAChRs for producing the postsynaptic current has been found to be higher than the affinity of presynaptic nAChRs (110), indicating that these presynaptic nAChRs of the medial habenula mediate their action via nonsynaptic transmission.

C. Pyramidal Neurons

In addition to nAChRs on hippocampal interneurons, there are functional dendritic nAChRs in pyramidal neurons of the hippocampus (44, 69). Earlier studies have shown nicotinic action only in a fraction of pyramidal neurons, which respond with small depolarizations corresponding to inward currents of 10–20 pA amplitude mediated by 7 nAChRs (111). Interestingly, other studies failed to resolve the function of these nAChRs (34, 72, 77). In cultured hippocampal neurons, roughly two-thirds of the cells can respond to nicotinic agonists with an 7 nAChR-mediated current (193). Activation of somatodendritic nAChRs of pyramidal neurons by puffs of nicotinic agonists evokes excitatory events and Ca²⁺ accumulation in acute slices (44, 69, 91) (Fig. 3).

View larger version (77K): [in this window] [in a new window]   FIG. 3. Firing induced by nicotine (250 µM) in CA1 pyramidal neurons. A: a collapsed two-photon image stack of a part of the apical dendrite. The cell was filled with the Ca2+-sensitive fluorescent dye Oregon green BAPTA-1. B: calcium transients corresponding to different action potential patterns as indicated. C: imaging in a line crossing the dendrite shown in A at 330 µm from the soma reveals increase in fluorescence indicative of changes in intracellular Ca2+ at high temporal resolution. D: firing activity (bottom) and Ca2+ dynamics (top) in different anatomical units of a small dendritic segment (on right). This fine secondary dendritic section contains two spines. Images are taken from the period as indicated by the corresponding numbers above the Ca2+ data. The color code of the boxes on the images indicates the trace of Ca2+ responses during and after focal nicotine application (image 1). The small spine responds to the initial action potential during the nicotine perfusion, while the larger spine remains inactive (image 2). The larger mushroom-type spine shows a large increase in fluorescence to nicotine (image 3).

	VI. NONSYNAPTIC NICOTINIC ACETYLCHOLINE RECEPTORS AND HIGHER BRAIN FUNCTIONS

Top Previous Next References

 
A. Role of Nonsynaptic nAChR in Smoking

Immediately after nicotine enters the brain during smoking, it augments the cholinergic route of reward; the blood level of nicotine in smokers reaches the firing threshold of VTA neurons leading to DA release in the nucleus accumbens (NAc) via nAChRs, which later desensitize leading to addiction (73). Nicotine in the brain most likely acts on high-affinity receptors because of the low concentration of the drug. Nicotine concentrations in the smoker's blood can vary between 250 and 500 nM for 10 min just after smoking a cigarette (55). During the first minute of smoking a cigarette, the blood level of nicotine goes up to 250 nM (55). Nicotine can remain at a low level (200 nM) for hours. Just before smoking a cigarette, the concentration of nicotine in the smoker's blood is 40 nM (55). Although nicotine accumulates in the brain with a greater concentration than in the blood, reaching a nearly fourfold increase (45), the final concentration is still too low to activate any synaptic receptor, because synaptic activation may require millimolar concentration of the endogenous agonist. Thus the conclusion must be drawn that nonsynaptic transmission is the dominant mode of action for the exogenous (smoked) nicotine. Nicotine reaches a maximal concentration around cells that is far below the concentration for activation of the sparse synaptic nAChRs. At the cellular level, nicotine can indeed activate nAChRs at concentrations that likely occur in the brain during smoking (4). There are experimental data showing that nicotine is able to activate receptors in spite of the rapid desensitization. Pretreatment with 40 nM nicotine fails to alter GABAergic responses to 1 µM nicotine, suggesting that nAChRs may have already recovered from desensitization by the time the blood level of nicotine drops down to 40 nM and are ready to be activated during the next cigarette (104). However, pretreatment with 250 nM nicotine could desensitize nAChR and abolish the GABAergic response to nicotine administration (104). Exposure to 0.5 µM nicotine for longer than 5 min can cause a deeper state of desensitization (123). The long half-life of nicotine and the slow recovery from desensitization may explain why smokers report that the first cigarette is the most pleasurable of the day (138). It has been shown that nicotine in nanomolar concentrations can interact with nAChRs in an 4-sensitized preparation (159) and may produce local Ca²⁺ responses in the nicotinic microdomain under normal circumstances. Thus even very low, nanomolar concentrations of nicotine are enough to produce small changes, which could be significant for local neural functions, most likely via high-affinity (extrasynaptic) receptors. It can be assumed that in contrast to the nicotine application during experiments, the synchronization of openings by low-dose nicotine is not complete in vivo, such that not all nAChRs become desensitized, with a few receptors escaping desensitization and remaining ready to open.

Nicotine at 1 µM causes a robust increase in the frequency of spontaneous GABAergic inhibitory postsynaptic currents in the VTA, indicating a role for presynaptic/preterminal nAChRs at GABAergic innervation (104). Presynaptic/preterminal 7 nAChRs, which are necessarily nonsynaptic receptors, contribute to long-term potentiation (LTP) induction in the VTA. The pairing of nicotine application with postsynaptic depolarization of VTA dopaminergic neurons potentiates the evoked EPSCs to form LTP (103). The glutamatergic transmission is still enhanced when the enhancement of GABAergic transmission by nicotine has already desensitized (104). Although nAChRs on VTA dopaminergic neurons desensitize rapidly, the sustained dopaminergic input to the NAc after nicotinic stimulation still exits because of the differential desensitization of the GABAergic and glutamatergic innervation: nAChRs on GABAergic neurons have already desensitized while nicotine is still able to enhance glutamatergic transmission, shifting the balance of synaptic inputs to prolonged excitation (104).

B. Therapeutic Potential of nAChR Stimulation on Cognition and Nonsynaptic Transmission

Further evidence for the nonsynaptic nature of nicotinic transmission comes from the effect of nicotine in human therapy. Nonsynaptic receptors located on extrasynaptic surfaces are activated by a low concentration of the agonist and are, therefore, characterized by high-affinity binding (177). High-affinity receptors and transporters are the major targets of medicines because drugs can reach only low concentration in the brain during clinical therapy (177). In the light of these considerations, it is not surprising that nicotine has therapeutic power in humans. The effect of nAChR stimulation in Alzheimer's disease (AD) is based on the experimental evidence that nicotine improves memory in animals, healthy subjects, and AD patients (118). Transdermal nicotine patches improve performance on a nonverbal learning task and increase attention performance in AD patients (133). The nicotinic agonist ABT-418 improves verbal learning and memory in AD patients (125), and administration of the nicotinic antagonist mecamylamine to elderly subjects and AD patients produces cognitive impairment (118). In addition, levels of different nAChRs decrease with age, which is even more pronounced in AD (118). The cortical nAChR deficits significantly correlate with cognitive impairment in AD patients (118). Positron emission tomography studies revealed reduced cortical AChE activity in AD patients (65). Cholinesterase inhibitors including tacrine, rivastigmine, and galantamine have been shown to slow the progression of AD in clinical studies (171). It is possible that these inhibitors, at least in part, act through direct activation of nAChRs (118). Nicotine skin patches attenuate the haloperidol-induced deficit in working memory tests (133). Animal models further support the human importance of nicotine therapy in AD by showing that nicotine can reduce β-amyloidosis in mice (117).

Supporting the observations of positive nicotinic effects in AD, there are numerous experimental data available showing that nicotine improves cognitive performance in deprived smokers and in patients with impaired cognition (115). The clearest effect of transdermal nicotine patches is an improvement of cognition in humans, which is reflected by the reduction in the number of errors of omission on the continuous performance task showing primarily the effect on attentional processes (133). It has been shown that long-term nicotine treatment can be important for improving cognitive function (170). In animal tests, both acute and chronic nicotine treatments have been shown to improve working memory (93, 133). Choice of accuracy significantly increased following nicotine administration in behavioral studies on rats, indicating the nicotinic effect on the working memory (133). Block of the nicotinic system shows the opposite: local infusion of mecamylamine into the hippocampus impairs working memory performance in rats (120). Mecamylamine and dihydro-β-erythroidine (DHβE) impair short- and long-term memory retrieval in behavioral tests on rats, while nicotine enhances it (106). The in vivo effects of DHβE or the 7 nAChR-specific methyllycaconitine (MLA) suggest a role for both 7 and non-7 receptors in memory formation in rats (94). In support of the clinical importance and effectiveness of nicotine therapy, it has been shown that people with schizophrenia smoke cigarettes at a very high rate, 80–90% compared with the 45–70% of patients with other psychiatric disorders and 30% of the general population (60). Schizophrenics have a deficient number of nAChRs in the hippocampus (36).

These data indicate that clinical pharmacotherapy, which mostly targets nonsynaptic receptors because of their high affinity (177), utilizes the beneficial effects of drugs on nAChRs, which highlights the importance of nonsynaptic communication in this context. Similarly, nicotine inhaled from smoking can reach only a low concentration in the brain; therefore, it can preferentially activate nonsynaptic nAChRs of high affinity. The low-affinity nAChRs situated in the nicotinic synapses of the brain are most likely silent during drug treatment or smoking.

	GRANTS

Top Previous Next References

 
This work was supported in part by Philip Morris USA Inc. and Philip Morris International, The Hungarian Research Fund (OTKA Ts 049868), and the Hungarian Medical Research Foundation.

	ACKNOWLEDGMENTS

Top References

 
Address for reprint requests and other correspondence: B. Lendvai, Institute of Experimental Medicine, Szigony U.43, H-1083 Budapest, Hungary (e-mail: lendvai{at}koki.hu).

	REFERENCES

Top

 

1. Adams CE, Stitzel JA, Collins AC, Freedman R. 7-Nicotinic receptor expression and the anatomical organization of hippocampal interneurons. Brain Res 922: 180–190, 2001.[CrossRef][Web of Science][Medline]
2. Alkondon M, Albuquerque EX. A non-7 nicotinic acetylcholine receptor modulates excitatory input to hippocampal CA1 interneurons. J Neurophysiol 87: 1651–1654, 2002.[Abstract/Free Full Text]
3. Alkondon M, Braga MF, Pereira EF, Maelicke A, Albuquerque EX. 7 Nicotinic acetylcholine receptors and modulation of GABAergic synaptic transmission in the hippocampus. Eur J Pharmacol 393: 59–67, 2000.[CrossRef][Web of Science][Medline]
4. Alkondon M, Pereira EF, Almeida LE, Randall WR, Albuquerque EX. Nicotine at concentrations found in cigarette smokers activates and desensitizes nicotinic acetylcholine receptors in CA1 interneurons of rat hippocampus. Neuropharmacology 39: 2726–39, 2000.[CrossRef][Web of Science][Medline]
5. Alkondon M, Pereira EF, Albuquerque EX. NMDA and AMPA receptors contribute to the nicotinic cholinergic excitation of CA1 interneurons in the rat hippocampus. J Neurophysiol 90: 1613–1625, 2003.[Abstract/Free Full Text]
6. Alkondon M, Pereira EF, Albuquerque EX. -Bungarotoxin- and methyllycaconitine-sensitive nicotinic receptors mediate fast synaptic transmission in interneurons of rat hippocampal slices. Brain Res 810: 257–263, 1998.[CrossRef][Web of Science][Medline]
7. Alkondon M, Pereira EF, Cortes WS, Maelicke A, Albuquerque EX. Choline is a selective agonist of 7 nicotinic acetylcholine receptors in the rat brain neurons. Eur J Neurosci 9: 2734–2742, 1997.[CrossRef][Web of Science][Medline]
8. Alkondon M, Pereira EF, Eisenberg HM, Albuquerque EX. Nicotinic receptor activation in human cerebral cortical interneurons: a mechanism for inhibition and disinhibition of neuronal networks. J Neurosci 20: 66–75, 2000.[Abstract/Free Full Text]
9. Alkondon M, Pereira EFR, Eisenberg HM, Albuquerque EX. Choline and selective antagonists identify two subtypes of nicotinic acetylcholine receptors that modulate GABA release from CA1 interneurons in rat hippocampal slices. J Neurosci 19: 2693–2705, 1999.[Abstract/Free Full Text]
10. Aramakis VB, Metherate R. Nicotine selectively enhances NMDA receptor-mediated synaptic transmission during postnatal development in sensory neocortex. J Neurosci 18: 8485–8495, 1998.[Abstract/Free Full Text]
11. Aznavour N, Watkins KC, Descarries L. Postnatal development of the cholinergic innervation in the dorsal hippocampus of rat: quantitative light and electron microscopic immunocytochemical study. J Comp Neurol 486: 61–75, 2005.[CrossRef][Web of Science][Medline]
12. Bennett BD, Wilson CJ. Spontaneous activity of neostriatal cholinergic interneurons in vitro. J Neurosci 19: 5586–5596, 1999.[Abstract/Free Full Text]
13. Brain KL, Trout SJ, Jackson VM, Dass N, Cunnane TC. Nicotine induces calcium spikes in single nerve terminal varicosities: a role for intracellular calcium stores. Neuroscience 106: 395–403, 2001.[CrossRef][Web of Science][Medline]
14. Buhler AV, Dunwiddie TV. 7 Nicotinic acetylcholine receptors on GABAergic interneurons evoke dendritic and somatic inhibition of hippocampal neurons. J Neurophysiol 87: 548–557, 2002.[Abstract/Free Full Text]
15. Buisson B, Bertrand D. Chronic exposure to nicotine upregulates the human 4β2 nicotinic acetylcholine receptor function. J Neurosci 21: 1819–1829, 2001.[Abstract/Free Full Text]
16. Champtiaux N, Changeux JP. Knockout and knockin mice to investigate the role of nicotinic receptors in the central nervous system. Prog Brain Res 145: 235–251, 2004.[Web of Science][Medline]
17. Chang KT, Berg DK. Nicotinic acetylcholine receptors containing 7 subunits are required for reliable synaptic transmission in situ. J Neurosci 19: 3701–3710, 1999.[Abstract/Free Full Text]
18. Changeux JP, Edelstein SJ. Nicotinic Acetylcholine Receptors, From Molecular Biology to Cognition. Baltimore, MD: Johns Hopkins Univ. Press, 2005.
19. Clark BA, Cull-Candy SG. Activity-dependent recruitment of extrasynaptic NMDA receptor activation at an AMPA receptor-only synapse. J Neurosci 22: 4428–4436, 2002.[Abstract/Free Full Text]
20. Clarke PBS, Reuben M. Release of [³H]-norepinephrine from rat hippocampal synaptosomes by nicotine: mediation by different nicotinic receptor subtypes from [³H]-dopamine release. Br J Pharmacol 117: 595–606, 1996.[Web of Science][Medline]
21. Cole AE, Nicoll RA. Acetylcholine mediates a slow synaptic potential in hippocampal pyramidal cells. Science 221: 1299–1301, 1983.[Abstract/Free Full Text]
22. Criswell MH, Brandon C. Acetylcholinesterase and choline acetyltransferase localization patterns do correspond in cat and rat retinas. Vision Res 33: 1747–1753, 1993.[CrossRef][Web of Science][Medline]
23. Cuevas J, Roth AL, Berg DK. Two distinct classes of functional 7-containing nicotinic receptor on rat superior cervical ganglion neurons. J Physiol 525: 735–746, 2000.[Abstract/Free Full Text]
24. Dajas-Bailador F, Costa G, Dajas F, Emmett S. Effects of -erabutoxin, -bungarotoxin, -cobratoxin and fasciculin on the nicotine-evoked release of dopamine in the rat striatum in vivo. Neurochem Int 33: 307–312, 1998.[CrossRef][Web of Science][Medline]
25. Descarries L, Lemay B, Doucet G, Berger B. Regional and laminar density of the dopamine innervation in adult rat cerebral cortex. Neuroscience 21: 807–824, 1987.[CrossRef][Web of Science][Medline]
26. Descarries L, Gisiger V, Steriade M. Diffuse transmission by acetylcholine in the CNS. Prog Neurobiol 53: 603–625, 1997.[CrossRef][Web of Science][Medline]
27. Descarries L, Mechawar N. Ultrastructural evidence for diffuse transmission by monoamine and acetylcholine neurons of the central nervous system. Prog Brain Res 125: 27–47, 2000.[Web of Science][Medline]
28. Dolezal V, Lee K, Schobert A, Hertting G. The influx and the release of norepinephrine evoked by stimulation of presynaptic nicotinic receptors of chick sympathetic neurons in culture are not mediated via L-, M-, or P-type calcium channels. Brain Res 740: 75–80, 1996.[CrossRef][Web of Science][Medline]
29. Dolezal V, Schobert A, Hertting G. Presynaptic nicotinic receptors stimulate increases in intraterminal calcium of chick sympathetic neurons in culture. J Neurochem 65: 1874–1879, 1995.[Web of Science][Medline]
30. El-Bizri H, Clarke PBS. Blockade of nicotinic receptor-mediated release of dopamine from striatal synaptosomes by chlorisondamine administered in vivo. Br J Pharmacol 111: 414–418, 1994.[Web of Science][Medline]
31. Fabian-Fine R, Skehel P, Errington ML, Davies HA, Sher E, Stewart MG, Fine A. Ultrastructural distribution of the 7 nicotinic acetylcholine receptor subunit in rat hippocampus. J Neurosci 21: 7993–8003, 2001.[Abstract/Free Full Text]
32. Fischer H, Orr-Urtreger A, Role LW, Huck S. Selective deletion of the -subunit differentially affects somatic-dendritic versus axonally targeted nicotinic ACh receptors in mouse. J Physiol 563: 119–137, 2005.[Abstract/Free Full Text]
33. Frazier CJ, Buhler AV, Weiner JL, Dunwiddie TV. Synaptic potentials mediated via -bungarotoxin-sensitive nicotinic acetylcholine receptors in rat hippocampal interneurons. J Neurosci 18: 8228–8235, 1998.[Abstract/Free Full Text]
34. Frazier CJ, Rollins YD, Breese CR, Leonard S, Freedman R, Dunwiddie TV. Acetylcholine activates an -bungarotoxin-sensitive nicotinic current in rat hippocampal interneurons, but not pyramidal cells. J Neurosci 18: 1187–1195, 1998.[Abstract/Free Full Text]
35. Frazier CJ, Strowbridge BW, Papke RL. Nicotinic acetylcholine receptors on local circuit neurons in the dentate gyrus: a potential role in the regulation of granule cell excitability. J Neurophysiol 89: 3018–3028, 2003.[Abstract/Free Full Text]
36. Freedman R, Hall M, Adler LE, Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 38: 22–33, 1995.[CrossRef][Web of Science][Medline]
37. Freedman R, Wetmore C, Stromberg I, Leonard S, Olson L. -Bungarotoxin binding to hippocampal interneurons: immunocytochemical characterization and effects on growth factor expression. J Neurosci 13: 1965–1975, 1993.[Abstract]
38. Freund RK, Jungschaffer DA, Collins AC. Nicotine effects in mouse hippocampus are blocked by mecamylamine, but not other nicotinic antagonists. Brain Res 511: 187–191, 1990.[CrossRef][Web of Science][Medline]
39. Freund TF, Buzsaki G. Interneurons of the hippocampus. Hippocampus 6: 347–470, 1996.[CrossRef][Web of Science][Medline]
40. Frotscher M, Leranth C. Cholinergic innervation of the rat hippocampus as revealed by choline acetyltransferase immunocytochemistry: a combined light and electron microscopic study. J Comp Neurol 239: 237–246, 1985.[CrossRef][Web of Science][Medline]
41. Frotscher M, Schlander M, Leranth C. Cholinergic neurons in the hippocampus. A combined light- and electron-microscopic immunocytochemical study in the rat. Cell Tissue Res 246: 293–301, 1986.[CrossRef][Web of Science][Medline]
42. Fuentealba J, Olivares R, Ales E, Tapia L, Rojo J, Arroyo G, Aldea M, Criado M, Gandia L, Garcia AG. A choline-evoked [Ca²⁺]_c signal causes catecholamine release and hyperpolarization of chromaffin cells. FASEB J 18: 1468–1470, 2004.[Abstract/Free Full Text]
43. Gahring LC, Persiyanov K, Dunn D, Weiss R, Meyer EL, Rogers SW. Mouse strain-specific nicotinic acetylcholine receptor expression by inhibitory interneurons and astrocytes in the dorsal hippocampus. J Comp Neurol 468: 334–346, 2004.[CrossRef][Web of Science][Medline]
44. Ge S, Dani JA. Nicotinic acetylcholine receptors at glutamate synapses facilitate long-term depression or potentiation. J Neurosci 25: 6084–6091, 2005.[Abstract/Free Full Text]
45. Ghosheh OA, Dwoskin LP, Miller DK, Crooks PA. Accumulation of nicotine and its metabolites in rat brain after intermittent or continuous peripheral administration of [2'-¹⁴C]nicotine. Drug Metab Dispos 29: 645–651, 2001.[Abstract/Free Full Text]
46. Gil Z, Connors BW, Amitai Y. Differential regulation of neocortical synapses by neuromodulators and activity. Neuron 19: 679–686, 1997.[CrossRef][Web of Science][Medline]
47. Girod R, Role LW. Long-lasting enhancement of glutamatergic synaptic transmission by acetylcholine contrasts with response adaptation after exposure to low-level nicotine. J Neurosci 21: 5182–5190, 2001.[Abstract/Free Full Text]
48. Girod R, Barazangi N, McGehee D, Role LW. Facilitation of glutamatergic neurotransmission by presynaptic nicotinic acetylcholine receptors. Neuropharmacology 39: 2715–2725, 2000.[CrossRef][Web of Science][Medline]
49. Gotti C, Clementi F. Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol 74: 363–396, 2004.[CrossRef][Web of Science][Medline]
50. Grady S, Marks MJ, Wonnacott S, Collins AC. Characterization of nicotinic receptor mediated [³H]-dopamine release from synaptosomes preapared from the mouse striatum. J Neurochem 59: 848–856, 1992.[Web of Science][Medline]
51. Graham AJ, Ray MA, Perry EK, Jaros E, Perry RH, Volsen SG, Bose S, Evans N, Lindstrom J, Court JA. Differential nicotinic acetylcholine receptor subunit expression in the human hippocampus. J Chem Neuroanat 25: 97–113, 2003.[CrossRef][Web of Science][Medline]
52. Gray R, Rajan AS, Radcliffe KA, Yakehiro M, Dani JA. Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature 383: 713–716, 1996.[CrossRef][Medline]
53. Hatton GI, Yang QZ. Synaptic potentials mediated by 7 nicotinic acetylcholine receptors in supraoptic nucleus. J Neurosci 22: 29–37, 2002.[Abstract/Free Full Text]
54. Hefft S, Hulo S, Bertrand D, Muller D. Synaptic transmission at nicotinic acetylcholine receptors in rat hippocampal organotypic cultures and slices. J Physiol 515: 769–776, 1999.[Abstract/Free Full Text]
55. Henningfield JE, Stapleton JM, Benowitz NL, Grayson RF, London ED. Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend 33: 23–29, 1993.[CrossRef][Web of Science][Medline]
56. Herber DL, Severance EG, Cuevas J, Morgan D, Gordon MN. Biochemical and histochemical evidence of nonspecific binding of 7nAChR antibodies to mouse brain tissue. J Histochem Cytochem 52: 1367–1376, 2004.[Abstract/Free Full Text]
57. Herkenham M. Mismatches between neurotransmitter and receptor localizations in brain: observations and implications. Neuroscience 23: 1–38, 1987.[CrossRef][Web of Science][Medline]
58. Hill JA, Zoli M, Bourgeois JP, Changeux JP. Immunocytochemical localization of neural nicotinic receptor: the β2-subunit. J Neurosci 13: 1551–1568, 1993.[Abstract]
59. Horch HL, Sargent PB. Perisynaptic surface distribution of multiple classes of nicotinic acetylcholine receptors on neurons in the chicken ciliary ganglion. J Neurosci 15: 7778–7795, 1995.[Abstract]
60. Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 143: 993–997, 1986.[Abstract/Free Full Text]
61. Hulo S, Muller D. Tetrodotoxin-sensitive enhancement of inhibition in CA1 pyramidal neurones by nicotine. Neuroreport 12: 1351–1354, 2001.[CrossRef][Web of Science][Medline]
62. Hunt S, Schmidt J. Some observations on the binding patterns of alpha-bungarotoxin in the central nervous system of the rat. Brain Res 157: 213–232, 1978.[CrossRef][Web of Science][Medline]
63. Hunt S, Schmidt J. The electron microscopic autoradiographic localization of alpha-bungarotoxin binding sites within the central nervous system of the rat. Brain Res 142: 152–159, 1978.[CrossRef][Web of Science][Medline]
64. Hunt S, Schmidt J. The relationship of -bungarotoxin binding activity and cholinergic termination within the rat hippocampus. Neuroscience 4: 585–592, 1979.[CrossRef][Web of Science][Medline]
65. Iyo M, Namba H, Fukushi K, Shinotoh H, Nagatsuka S, Suhara T, Sudo Y, Suzuki K, Irie T. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet 349: 1805–1809, 1997.[CrossRef][Web of Science][Medline]
66. Jacob MH, Berg DK. The ultrastructural localization of alpha-bungarotoxin binding sites in relation to synapses on chick ciliary ganglion neurons. J Neurosci 3: 260–271, 1983.[Abstract]
67. Jayasundar S, Vohra MM. Mechanism of nicotine-induced release of norepinephrine from adrenergic nerve endings: is generation and propagation of impulses necessary? Arch Int Pharmacodyn Ther 232: 202–210, 1978.[Web of Science][Medline]
68. Ji D, Dani JA. Inhibition and disinhibition of pyramidal neurons by activation of nicotinic receptors on hippocampal interneurons. J Neurophysiol 83: 2682–2690, 2000.[Abstract/Free Full Text]
69. Ji D, Lape R, Dani JA. Timing and location of nicotinic activity enhances or depresses hippocampal synaptic plasticity. Neuron 31: 131–141, 2001.[CrossRef][Web of Science][Medline]
70. Jones IW, Wonnacott S. Precise localization of 7 nicotinic acetylcholine receptors on glutamatergic axon terminals in the rat ventral tegmental area. J Neurosci 24: 11244–11252, 2004.[Abstract/Free Full Text]
71. Jones IW, Wonnacott S. Why doesn't nicotinic ACh receptor immunoreactivity knock out? Trends Neurosci 28: 343–345, 2005.[CrossRef][Web of Science][Medline]
72. Jones S, Yakel JL. Functional nicotinic ACh receptors on interneurones in the rat hippocampus. J Physiol 504: 603–610, 1997.[Abstract/Free Full Text]
73. Jones S, Sudweeks S, Yakel JL. Nicotinic receptors in the brain: correlating physiology with function. Trends Neurosci 22: 555–561, 1999.[CrossRef][Web of Science][Medline]
74. Kása P, Hlavati I, Dobo E, Wolff A, Joo F, Wolff JR. Synaptic and non-synaptic cholinergic innervation of the various types of neurons in the main olfactory bulb of adult rat: immunocytochemistry of choline acetyltransferase. Neuroscience 67: 667–677, 1995.[CrossRef][Web of Science][Medline]
75. Kawai H, Zago W, Berg DK. Nicotinic 7 receptor clusters on hippocampal GABAergic neurons: regulation by synaptic activity and neurotrophins. J Neurosci 22: 7903–7912, 2002.[Abstract/Free Full Text]
76. Kawaja MD, Flumerfelt BA, Hrycyshyn AW. A comparison of the subnuclear and ultrastructural distribution of acetylcholinesterase and choline acetyltransferase in the rat interpeduncular nucleus. Brain Res Bull 24: 517–523, 1990.[CrossRef][Web of Science][Medline]
77. Khiroug L, Giniatullin R, Klein RC, Fayuk D, Yakel JL. Functional mapping and Ca²⁺ regulation of nicotinic acetylcholine receptor channels in rat hippocampal CA1 neurons. J Neurosci 23: 9024–9031, 2003.[Abstract/Free Full Text]
78. Khiroug L, Giniatullin R, Sokolova E, Talantova M, Nistri A. Imaging of intracellular calcium during desensitization of nicotinic acetylcholine receptors of rat chromaffin cells. Br J Pharmacol 122: 1323–1332, 1997.[CrossRef][Web of Science][Medline]
79. Kiss JP, Sershen H, Lajtha A, Vizi ES. Inhibition of neuronal nitric oxide synthase potentiates the dimethylphenylpiperazinium-evoked carrier-mediated release of noradrenaline from rat hippocampal slices. Neurosci Lett 215: 115–118, 1996.[CrossRef][Web of Science][Medline]
80. Kiss JP, Vizi ES, Westerink BHC. Effect of neostigmine on the hippocampal noradrenaline release: role of cholinergic receptors. Neuroreport 10: 81–86, 1999.[Web of Science][Medline]
81. Kiss JP, Windisch K, Balla A, Sershen H, Lajtha A. Dual effect of DMPP on the resting release of noradrenaline from rat hippocampal slices. Brain Res Bull 43: 254–262, 1997.
82. Kiss JP, Windisch K, De Oliveira K, Hennings EC, Mike A, Szasz BK. Differential effect of nicotinic agonists on the [³H]norepinephrine release from rat hippocampal slices. Neurochem Res 26: 943–950, 2001.[CrossRef][Web of Science][Medline]
83. Kofalvi A, Sperlagh B, Zelles T, Vizi ES. Long-lasting facilitation of 4-amino-n-[2,3-³H]butyric acid ([³H]GABA) release from rat hippocampal slices by nicotinic receptor activation. J Pharmacol Exp Ther 295: 453–462, 2000.[Abstract/Free Full Text]
84. Koos T, Tepper JM. Dual cholinergic control of fast-spiking interneurons in the neostriatum. J Neurosci 22: 529–535, 2002.[Abstract/Free Full Text]
85. Kristufek D, Stocker E, Boehm S, Huck S. Somatic and prejunctional nicotinic receptors in cultured rat sympathetic neurones show different agonist profiles. J Physiol 516: 739–756, 1999.[Abstract/Free Full Text]
86. Kulak JM, Nguyen TA, Olivera BM, McIntosh JM. -Conotoxin MII blocks nicotine-stimulated dopamine release in rat striatal synaptosomes. J Neurosci 17: 5263–5270, 1997.[Abstract/Free Full Text]
87. Le Novere N, Changeux JP. Molecular evolution of the nicotinic acetylcholine receptor: an example of multigene family in excitable cells. J Mol Evol 40: 155–172, 1995.[CrossRef][Web of Science][Medline]
88. Lena C, Changeux JP. Role of Ca²⁺ ions in nicotinic facilitation of GABA release in mouse thalamus. J Neurosci 17: 576–585, 1997.[Abstract/Free Full Text]
89. Lena C, Changeux JP, Mulle C. Evidence for "preterminal" nicotine receptors on GABAergic axons in the rat interpeduncular nucleus. J Neurosci 13: 2680–2688, 1993.[Abstract]
90. Lendvai B, Sershen H, Lajtha A, Santha E, Baranyi M, Vizi ES. Differential mechanisms involved in the effect of nicotinic agonists DMPP and lobeline to release [³H]5-HT from rat hippocampal slices. Neuropharmacology 35: 1769–1777, 1996.[CrossRef][Web of Science][Medline]
91. Lendvai B, Szabo SI, Barth AI, Zelles T, Vizi ES. Application of two-photon microscopy to the study of cellular pharmacology of central neurons. Adv Drug Deliv Rev 58: 841–849, 2006.[CrossRef][Web of Science][Medline]
92. Levey AI, Wainer BH, Rye DB, Mufson EJ, Mesulam MM. Choline acetyltransferase-immunoreactive neurons intrinsic to rodent cortex and distinction from acetylcholinesterase-positive neurons. Neuroscience 13: 341–353, 1984.[CrossRef][Web of Science][Medline]
93. Levin ED, Simon BB. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology 138: 217–230, 1998.[CrossRef][Medline]
94. Levin ED, Bradley A, Addy N, Sigurani N. Hippocampal 7 and β nicotinic receptors and working memory. Neuroscience 109: 757–765, 2002.[CrossRef][Web of Science][Medline]
95. Li X, Rainnie DG, McCarley RW, Greene RW. Presynaptic nicotinic receptors facilitate monoaminergic transmission. J Neurosci 18: 1904–1912, 1998.[Abstract/Free Full Text]
96. Liang SD, Vizi ES. Positive feedback modulation of acetylcholine release from isolated superior cervical ganglion. J Pharmacol Exp Ther 280: 650–655, 1997.[Abstract/Free Full Text]
97. Long C, Chen MF, Sarwinski SJ, Chen PY, Si M, Hoffer BJ, Evans MS, Lee TJ. Monoamine uptake inhibitors block -nAChR-mediated cerebral nitrergic neurogenic vasodilation. Am J Physiol Heart Circ Physiol 291: H202–H209, 2006.[Abstract/Free Full Text]
98. Luo S, Kulak JM, Cartier GE, Jacobsen RB, Yoshikami D, Olivera BM, McIntosh JM. -Conotoxin AuIB selectively blocks 3 β4 nicotinic acetylcholine receptors and nicotine-evoked norepinephrine release. J Neurosci 18: 8571–8579, 1998.[Abstract/Free Full Text]
99. Madison DV, Lancaster B, Nicoll RA. Voltage clamp analysis of cholinergic action in the hippocampus. J Neurosci 7: 733–741, 1987.[Abstract]
100. Maggi L, Le Magueresse C, Changeux JP, Cherubini E. Nicotine activates immature "silent" connections in the developing hippocampus. Proc Natl Acad Sci USA 100: 2059–2064, 2003.[Abstract/Free Full Text]
101. Maggi L, Sher E, Cherubini E. Regulation of GABA release by nicotinic acetylcholine receptors in the neonatal rat hippocampus. J Physiol 536: 89–100, 2001.[Abstract/Free Full Text]
102. Mandelzys A, Pie B, Deneris ES, Cooper E. The developmental increase in ACh current densities on rat sympathetic neurons correlates with changes in nicotinic ACh receptor alpha-subunit gene expression and occurs independent of innervation. J Neurosci 14: 2357–2364, 1994.[Abstract]
103. Mansvelder HD, McGehee DS. Long-term potentiation of excitatory inputs to brain reward areas by nicotine. Neuron 27: 349–357, 2000.[CrossRef][Web of Science][Medline]
104. Mansvelder HD, Keath JR, McGehee DS. Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron 33: 905–919, 2002.[CrossRef][Web of Science][Medline]
105. Marshall DL, Soliakov L, Redfern PH, Wonnacott S. Tetrodotoxin-sensitivity of nicotine-induced dopamine release from rat striatum. Neuropharmacology 35: 1531–1536, 1996.[CrossRef][Web of Science][Medline]
106. Marti Barros D, Ramirez MR, Dos Reis EA, Izquierdo I. Participation of hippocampal nicotinic receptors in acquisition, consolidation and retrieval of memory for one trial inhibitory avoidance in rats. Neuroscience 126: 651–656, 2004.[CrossRef][Web of Science][Medline]
107. Marubio LM, Changeux JP. Knockout mice as animal models for studying nicotinic acetylcholine receptor function. In: Handbook of Experimental Pharmacology. Neuronal Nicotinic Receptors, edited by Clementi F, Fronasari D, Gotti C. Berlin: Springer, 2000, p. 525–538.
108. Matsubayashi H, Amano T, Seki T, Sasa M, Sakai N. Postsynaptic 4β2 and 7 type nicotinic acetylcholine receptors contribute to the local and endogenous acetylcholine-mediated synaptic transmissions in nigral dopaminergic neurons. Brain Res 1005: 1–8, 2004.[CrossRef][Web of Science][Medline]
109. McGehee DS, Role LW. Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu Rev Physiol 57: 521–546, 1995.[CrossRef][Web of Science][Medline]
110. McGehee DS, Heath MJ, Gelber S, Devay P, Role LW. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science 269: 1692–1696, 1995.[Abstract/Free Full Text]
111. McQuiston AR, Madison DV. Nicotinic receptor activation excites distinct subtypes of interneurons in the rat hippocampus. J Neurosci 19: 2887–2896, 1999.[Abstract/Free Full Text]
112. Mechawar N, Watkins KC, Descarries L. Ultrastructural features of the acetylcholine innervation in the developing parietal cortex of rat. J Comp Neurol 443: 250–258, 2002.[CrossRef][Web of Science][Medline]
113. Mesulam MM, Guillozet A, Shaw P, Levey A, Duysen EG, Lockridge O. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience 110: 627–639, 2002.[CrossRef][Web of Science][Medline]
114. Mulle C, Lena C, Changeux JP. Potentiation of nicotinic receptor response by external calcium in rat central neurons. Neuron 8: 937–945, 1992.[CrossRef][Web of Science][Medline]
115. Newhouse PA, Potter A, Singh A. Effects of nicotinic stimulation on cognitive performance. Curr Opin Pharmacol 4: 36–46, 2004.[CrossRef][Web of Science][Medline]
116. Nicholson C, Sykova E. Extracellular space structure revealed by diffusion analysis. Trends Neurosci 21: 207–215, 1998.[CrossRef][Web of Science][Medline]
117. Nordberg A, Hellstrom-Lindahl E, Lee M, Johnson M, Mousavi M, Hall R, Perry E, Bednar I, Court J. Chronic nicotine treatment reduces beta-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw). J Neurochem 81: 655–658, 2002.[CrossRef][Web of Science][Medline]
118. Nordberg A. Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications. Biol Psychiatry 49: 200–210, 2001.[CrossRef][Web of Science][Medline]
119. Nusser Z, Sieghart W, Somogyi P. Segregation of different GABA_A receptors to synaptic and extrasynaptic membranes of cerebellar granule cells. J Neurosci 18: 1693–1703, 1998.[Abstract/Free Full Text]
120. Ohno M, Yamamoto T, Watanabe S. Blockade of hippocampal nicotinic receptors impairs working memory but not reference memory in rats. Pharmacol Biochem Behav 45: 89–93, 1993.[CrossRef][Web of Science][Medline]
121. Perry DC, Xiao Y, Nguyen HN, Musachio JL, Davila-Garcia MI, Kellar KJ. Measuring nicotinic receptors with characteristics of 4β2, 3β2, and 3β4 subtypes in rat tissues by autoradiography. J Neurochem 82: 468–481, 2002.[CrossRef][Web of Science][Medline]
122. Perry EK, Court JA, Johnson M, Smith CJ, James V, Cheng AV, Kerwin JM, Morris CM, Piggott MA, Edwardson JA, Birdsall NFM, Turner FT, Perry RH. Autoradiographic comparison of cholinergic and other transmitter receptors in the normal human hippocampus. Hippocampus 3: 307–315, 1993.[CrossRef][Web of Science][Medline]
123. Pidoplichko VI, DeBiasi M, Williams JT, Dani JA. Nicotine activates and desensitizes midbrain dopamine neurons. Nature 390: 401–404, 1997.[CrossRef][Medline]
124. Porter JT, Cauli B, Tsuzuki K, Lambolez B, Rossier J, Audinat E. Selective excitation of subtypes of neocortical interneurons by nicotinic receptors. J Neurosci 19: 5228–5235, 1999.[Abstract/Free Full Text]
125. Potter A, Corwin J, Lang J, Piasecki M, Lenox R, Newhouse PA. Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease. Psychopharmacology 142: 334–342, 1999.[CrossRef][Medline]
126. Power JM, Sah P. Nuclear calcium signaling evoked by cholinergic stimulation in hippocampal CA1 pyramidal neurons. J Neurosci 22: 3454–3462, 2002.[Abstract/Free Full Text]
127. Radcliffe KA, Dani JA. Nicotinic stimulation produces multiple forms of increased glutamatergic synaptic transmission. J Neurosci 18: 7075–7083, 1998.[Abstract/Free Full Text]
128. Rao TS, Correa LD, Lloyd GK. Effects of lobeline and dimethylphenylpiperazinium iodide (DMPP) on N-methyl-D-aspartate (NMDA)-evoked acetylcholine release in vitro: evidence for a lack of involvement of classical neuronal nicotinic receptors. Neuropharmacology 36: 39–50, 1997.[CrossRef][Web of Science][Medline]
129. Rassadi S, Krishnaswamy A, Pie B, McConnell R, Jacob MH, Cooper E. A null mutation for the 3 nicotinic acetylcholine (ACh) receptor gene abolishes fast synaptic activity in sympathetic ganglia and reveals that ACh output from developing preganglionic terminals is regulated in an activity-dependent retrograde manner. J Neurosci 25: 8555–8566, 2005.[Abstract/Free Full Text]
130. Reece LJ, Schwartzkroin PA. Effects of cholinergic agonists on two non-pyramidal cell types in rat hippocampal slices. Brain Res 566: 115–126, 1991.[CrossRef][Web of Science][Medline]
131. Reece LJ, Schwartzkroin PA. Nicotine exerts differential effects on different CA1 hippocampal cell types. Brain Res 540: 287–290, 1991.[CrossRef][Web of Science][Medline]
132. Reuben M, Clarke PB. Nicotine-evoked [³H]5-hydroxytryptamine release from rat striatal synaptosomes. Neuropharmacology 39: 290–299, 2000.[CrossRef][Web of Science][Medline]
133. Rezvani AH, Levin ED. Cognitive effects of nicotine. Biol Psychiatry 49: 258–267, 2001.[CrossRef][Web of Science][Medline]
134. Roerig B, Nelson DA, Katz LC. Fast synaptic signaling by nicotinic acetylcholine and serotonin 5-HT₃ receptors in developing visual cortex. J Neurosci 17: 8353–8362, 1997.[Abstract/Free Full Text]
135. Rousseau SJ, Jones IW, Pullar IA, Wonnacott S. Presynaptic 7 and non-7 nicotinic acetylcholine receptors modulate [³H]D-aspartate release from rat frontal cortex in vitro. Neuropharmacology 49: 59–72, 2005.[CrossRef][Web of Science][Medline]
136. Rovira C, Ben-Ari Y, Cherubini E, Krnjevic K, Ropert N. Pharmacology of the dendritic action of acetylcholine and further observations on the somatic disinhibition in the rat hippocampus in situ. Neuroscience 8: 97–106, 1983.[CrossRef][Web of Science][Medline]
137. Rubboli F, Court JA, Sala C, Morris C, Chini B, Perry E, Clementi F. Distribution of nicotinic receptors in the human hippocampus and thalamus. Eur J Neurosci 6: 1596–1604, 1994.[CrossRef][Web of Science][Medline]
138. Russell MA. Subjective and behavioural effects of nicotine in humans: some sources of individual variation. Prog Brain Res 79: 289–302, 1989.[Web of Science][Medline]
139. Sacaan AI, Dunlop JL, Lloyd GR. Pharmacological characterization of neuronal acetylcholine gated ion channel receptor-mediated hippocampal norepinephrine and striatal dopamine release from rat brain slices. J Pharmacol Exp Ther 274: 224–230, 1995.[Abstract/Free Full Text]
140. Sandor NT, Zelles T, Kiss JP, Sershen H, Torocsik A, Lajtha A, Vizi ES. Effect of nicotine on dopaminergic-cholinergic interaction in the striatum. Brain Res 567: 313–316, 1991.[CrossRef][Web of Science][Medline]
141. Santha E, Sperlagh B, Zelles T, Zsilla G, Toth PT, Lendvai B, Baranyi M, Vizi ES. Multiple cellular mechanisms mediate the effect of lobeline on the release of norepinephrine. J Pharmacol Exp Ther 294: 302–307, 2000.[Abstract/Free Full Text]
142. Sasakawa N, Ishii K, Kato R. Nicotinic receptor-mediated intracellular calcium release in cultured bovine adrenal chromaffin cells. Neurosci Lett 63: 275–279, 1986.[CrossRef][Web of Science][Medline]
143. Schilström B, Nomikos GG, Nisell M, Hertel P, Svensson TH. N-methyl-D-aspartate receptor antagonism in the ventral tegmental area diminishes the systemic nicotine-induced dopamine release in the nucleus accumbens. Neuroscience 82: 781–789, 1998.[Web of Science][Medline]
144. Scimemi A, Fine A, Kullmann DM, Rusakov DA. NR2B-containing receptors mediate cross talk among hippocampal synapses. J Neurosci 4: 4767–4777, 2004.
145. Seguela P, Wadiche J, Dineley-Miller K, Patrick JW. Molecular cloning, functional properties, distribution of rat brain 7: a nicotinic cation channel highly permeable to calcium. J Neurosci 13: 596–604, 1993.[Abstract]
146. Sershen H, Balla A, Lajtha A, Vizi ES. Characterization of nicotinic receptors involved in the release of norepinephrine from hippocampus. Neuroscience 77: 121–130, 1997.[CrossRef][Web of Science][Medline]
147. Severance EG, Zhang H, Cruz Y, Pakhlevaniants S, Hadley SH, Amin J, Wecker L, Reed C, Cuevas J. The 7 nicotinic acetylcholine receptor subunit exists in two isoforms that contribute to functional ligand-gated ion channels. Mol Pharmacol 66: 420–429, 2004.[Abstract/Free Full Text]
148. Sharma G, Vijayaraghavan S. Modulation of presynaptic store calcium induces release of glutamate and postsynaptic firing. Neuron 38: 929–939, 2003.[CrossRef][Web of Science][Medline]
149. Sharma G, Vijayaraghavan S. Nicotinic receptor signaling in nonexcitable cells. J Neurobiol 53: 524–534, 2002.[CrossRef][Web of Science][Medline]
150. Shoop RD, Chang KT, Ellisman MH, Berg DK. Synaptically driven calcium transients via nicotinic receptors on somatic spines. J Neurosci 21: 771–781, 2001.[Abstract/Free Full Text]
151. Shytle RD, Mori T, Townsend K, Vendrame M, Sun N, Zeng J, Ehrhart J, Silver AA, Sanberg PR, Tan J. Cholinergic modulation of microglial activation by 7 nicotinic receptors. J Neurochem 89: 337–343, 2004.[CrossRef][Web of Science][Medline]
152. Smiley JF, Morrell F, Mesulam MM. Cholinergic synapses in human cerebral cortex: an ultrastructural study in serial sections. Exp Neurol 144: 361–368, 1997.[CrossRef][Web of Science][Medline]
153. Soliakov L, Wonnacott S. Voltage sensitive Ca²⁺ channels involved in nicotinic receptor-mediated [³H]dopamine release from rat striatal synaptosomes. J Neurochem 67: 163–170, 1996.[Web of Science][Medline]
154. Stell BM, Mody I. Receptors with different affinities mediate phasic and tonic GABA_A conductances in hippocampal neurons. J Neurosci 22: RC223, 2002.[Abstract/Free Full Text]
155. Sudweeks SN, Yakel JL. Functional and molecular characterization of neuronal nicotinic ACh receptors in rat CA1 hippocampal neurons. J Physiol 527: 515–528, 2000.[Abstract/Free Full Text]
156. Szasz BK, Mayer A, Zsilla G, Lendvai B, Vizi ES, Kiss JP. Carrier-mediated release of monoamines induced by the nicotinic acetylcholine receptor agonist DMPP. Neuropharmacology 49: 400–409, 2005.[CrossRef][Web of Science][Medline]
157. Takahashi T, Tsunoda Y, Lu Y, Wiley J, Owyang C. Nicotinic receptor evoked release of acetylcholine and somatostatin in the myenteric plexus is coupled to calcium influx via N-type calcium channels. J Pharmacol Exp Ther 263: 1–5, 1992.[Abstract/Free Full Text]
158. Taly A, Corringer PJ, Grutter T, Prado de Carvalho L, Karplus M, Changeux JP. Implications of the quaternary twist allosteric model for the physiology and pathology of nicotinic acetylcholine receptors. Proc Natl Acad Sci USA 103: 16965–16970, 2006.[Abstract/Free Full Text]
159. Tapper AR, McKinney SL, Nashmi R, Schwarz J, Deshpande P, Labarca C, Whiteaker P, Marks MJ, Collins AC, Lester HA. Nicotine activation of 4* receptors: sufficient for reward, tolerance, sensitization. Science 306: 1029–1032, 2004.[Abstract/Free Full Text]
160. Teaktong T, Graham A, Court J, Perry R, Jaros E, Johnson M, Hall R, Perry E. Alzheimer's disease is associated with a selective increase in alpha7 nicotinic acetylcholine receptor immunoreactivity in astrocytes. Glia 41: 207–211, 2003.[CrossRef][Web of Science][Medline]
161. Teng L, Crooks PA, Sonsalla PK, Dwoskin LP. Lobeline and nicotine evoke [³H] overflow from rat striatal slices preloaded with [³H]dopamine: differential inhibition of synaptosomal and vesicular [³H]dopamine uptake. J Pharmacol Exp Ther 280: 1432–1444, 1997.[Abstract/Free Full Text]
162. Toth E, Vizi ES, Lajtha A. Effect of nicotine on the levels of extracellular amino acids in regions of the rat brain in vivo. Neuropharmacology 32: 827–832, 1993.[CrossRef][Web of Science][Medline]
163. Toth K, Freund TF, Miles R. Disinhibition of rat hippocampal pyramidal cells by GABAergic afferents from the septum. J Physiol 500: 463–474, 1997.[Abstract/Free Full Text]
164. Towart LA, Alves SE, Znamensky V, Hayashi S, McEwen BS, Milner TA. Subcellular relationships between cholinergic terminals and estrogen receptor-alpha in the dorsal hippocampus. J Comp Neurol 463: 390–401, 2003.[CrossRef][Web of Science][Medline]
165. Turner TJ. Nicotine enhancement of dopamine release by a calcium-dependent increase in the size of the readily releasable pool of synaptic vesicles. J Neurosci 24: 11328–11336, 2004.[Abstract/Free Full Text]
166. Turrini P, Casu MA, Wong TP, De Koninck Y, Ribeiro-da-Silva A, Cuello AC. Cholinergic nerve terminals establish classical synapses in the rat cerebral cortex: synaptic pattern and age-related atrophy. Neuroscience 105: 277–285, 2001.[CrossRef][Web of Science][Medline]
167. Ullian EM, Sargent PB. Pronounced cellular diversity and extrasynaptic location of nicotinic acetylcholine receptor subunit immunoreactivities in the chicken pretectum. J Neurosci 15: 7012–7023, 1995.[Abstract]
168. Umbriaco D, Garcia S, Beaulieu C, Descarries L. Relational features of acetylcholine, noradrenaline, serotonin and GABA axon terminals in the stratum radiatum of adult rat hippocampus (CA1). Hippocampus 5: 605–620, 1995.[CrossRef][Web of Science][Medline]
169. Umbriaco D, Watkins KC, Descarries L, Cozzari C, Hartman BK. Ultrastructural and morphometric features of the acetylcholine innervation in adult rat parietal cortex: an electron microscopic study in serial sections. J Comp Neurol 348: 351–373, 1994.[CrossRef][Web of Science][Medline]
170. Uzum G, Diler AS, Bahcekapili N, Tasyurekli M, Ziylan YZ. Nicotine improves learning and memory in rats: morphological evidence for acetylcholine involvement. Int J Neurosci 114: 1163–1179, 2004.[CrossRef][Web of Science][Medline]
171. VanDenBerg CM, Kazmi Y, Jann MW. Cholinesterase inhibitors for the treatment of Alzheimer's disease in the elderly. Drugs Aging 16: 123–138, 2000.[CrossRef][Web of Science][Medline]
172. Wanaverbecq N, Semyanov A, Pavlov I, Walker MC, Kullmann DM. Cholinergic axons modulate GABAergic signaling among hippocampal interneurons via postsynaptic 7 nicotinic receptors. J Neurosci 27: 5683–5693, 2007.[Abstract/Free Full Text]
173. Vernino S, Amador M, Luetje CW, Patrick J, Dani JA. Calcium modulation and high calcium permeability of neuronal nicotinic acetylcholine receptors. Neuron 8: 127–134, 1992.[CrossRef][Web of Science][Medline]
174. Vijayaraghavan S, Pugh PC, Zhang ZW, Rathouz MM, Berg DK. Nicotinic receptors that bind agr-bungarotoxin on neurons raise intracellular free Ca²⁺. Neuron 8: 353–362, 1992.[CrossRef][Web of Science][Medline]
175. Vizi ES. Non-synaptic modulation of transmitter release: pharmacological implication. Trends Pharmacol Sci 1: 172–175, 1980.[CrossRef]
176. Vizi ES. Nonsynaptic Interactions Between Neurons: Modulation of Neurochemical Transmission. New York: Wiley, 1984.
177. Vizi ES. Role of high-affinity receptors, membrane transporters in nonsynaptic communication and drug action in the central nervous system. Pharmacol Rev 52: 63–89, 2000.[Abstract/Free Full Text]
178. Vizi ES, Palkovits M. Acetylcholine content in different regions of the rat brain. Brain Res Bull 3: 93–96, 1978.[CrossRef][Web of Science][Medline]
179. Vizi ES, Sershen H, Balla A, Mike A, Windish K, Juranyi ZS, Lajtha A. Neurochemical evidence of heterogeneity of presynaptic and somatodendritic nicotinic acetylcholine receptors. Ann NY Acad Sci 757: 84–99, 1995.[Web of Science][Medline]
180. Vizi ES, Kiss JP. Neurochemistry and pharmacology of the major hippocampal transmitter systems: synaptic and nonsynaptic interactions. Hippocampus 8: 566–607, 1998.[CrossRef][Web of Science][Medline]
181. Vizi ES, Lendvai B. Modulatory role of presynaptic nicotinic receptors in synaptic and non-synaptic chemical communication in the central nervous system. Brain Res Rev 30: 219–235, 1999.[CrossRef][Medline]
182. Vizi ES, Kiss JP, Lendvai B. Nonsynaptic communication in the central nervous system. Neurochem Int 45: 443–451, 2004.[CrossRef][Web of Science][Medline]
183. Vizi ES, Rozsa B, Mayer A, Kiss JP, Zelles T, Lendvai B. Further evidence for the functional role of nonsynaptic nicotinic acetylcholine receptors. Eur J Pharmacol 500: 499–508, 2004.[CrossRef][Web of Science][Medline]
184. Vogt KE, Regehr WG. Cholinergic modulation of excitatory synaptic transmission in the CA3 area of the hippocampus. J Neurosci 21: 75–83, 2001.[Abstract/Free Full Text]
185. Wang BW, Liao WN, Chang CT, Wang SJ. Facilitation of glutamate release by nicotine involves the activation of a Ca²⁺/calmodulin signaling pathway in rat prefrontal cortex nerve terminals. Synapse 59: 491–501, 2006.[CrossRef][Web of Science][Medline]
186. Williams BM, Temburni MK, Levey MS, Bertrand S, Bertrand D, Jacob MH. The long internal loop of the 3 subunit targets nAChRs to subdomains within individual synapses on neurons in vivo. Nat Neurosci 1: 557–562, 1998.[CrossRef][Web of Science][Medline]
187. Wonnacott S, Irons J, Rapier C, Thorne B, Lunt GG. Presynaptic modulation of transmitter release by nicotinic receptors. Prog Brain Res 79: 157–163, 1989.[Web of Science][Medline]
188. Wonnacott S, Soliakov L, Wilkie G, Redfern P, Marshall D. Presynaptic nicotinic acetylcholine receptors in the brain. Drug Dev Res 38: 149–159, 1996.[CrossRef][Web of Science]
189. Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci 20: 92–98, 1997.[CrossRef][Web of Science][Medline]
190. Xiang Z, Huguenard JR, Prince DA. Cholinergic switching within neocortical inhibitory networks. Science 281: 985–988, 1998.[Abstract/Free Full Text]
191. Xiu J, Nordberg A, Zhang JT, Guan ZZ. Expression of nicotinic receptors on primary cultures of rat astrocytes and up-regulation of the 7, 4 and β2 subunits in response to nanomolar concentrations of the β-amyloid peptide(1-42). Neurochem Int 47: 281–290, 2005.[CrossRef][Web of Science][Medline]
192. Yamamoto S, Yamada J, Ueno S, Kubota H, Furukawa T, Yamamoto S, Fukuda A. Insertion of 7 nicotinic receptors at neocortical layer V GABAergic synapses is induced by a benzodiazepine, midazolam. Cereb Cortex 17: 653–660, 2007.[Abstract/Free Full Text]
193. Zarei MM, Radcliffe KA, Chen D, Patrick JW, Dani JA. Distributions of nicotinic acetylcholine receptor 7 and β2 subunits on cultured hippocampal neurons. Neuroscience 88: 755–764, 1999.[CrossRef][Web of Science][Medline]
194. Zhang ZW, Coggan JS, Berg DK. Synaptic currents generated by neuronal acetylcholine receptors sensitive to -bungarotoxin. Neuron 17: 1231–1240, 1996.[CrossRef][Web of Science][Medline]
195. Zhou FM, Liang Y, Dani JA. Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum. Nat Neurosci 4: 1224–1229, 2001.[CrossRef][Web of Science][Medline]

This article has been cited by other articles:

				K. Solt, E. W. Kelly, J. F. Cotten, and D. E. Raines Inhibition of Human {alpha}4{beta}2 Neuronal Nicotinic Acetylcholine Receptors by Volatile Aromatic Anesthetics Depends on Drug Hydrophobicity Anesth. Analg., February 1, 2010; 110(2): 455 - 460. [Abstract] [Full Text] [PDF]

				M. Sabatelli, F. Eusebi, A. Al-Chalabi, A. Conte, F. Madia, M. Luigetti, I. Mancuso, C. Limatola, F. Trettel, F. Sobrero, et al. Rare missense variants of neuronal nicotinic acetylcholine receptor altering receptor function are associated with sporadic amyotrophic lateral sclerosis Hum. Mol. Genet., October 15, 2009; 18(20): 3997 - 4006. [Abstract] [Full Text] [PDF]

				P. Aracri, S. Consonni, R. Morini, M. Perrella, S. Rodighiero, A. Amadeo, and A. Becchetti Tonic Modulation of GABA Release by Nicotinic Acetylcholine Receptors in Layer V of the Murine Prefrontal Cortex Cereb Cortex, October 7, 2009; (2009) bhp214v1. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lendvai, B. Articles by Vizi, E. S. Search for Related Content PubMed PubMed Citation Articles by Lendvai, B. Articles by Vizi, E. S.